Marshall E. Kadin

Dr. Marshall E. Kadin

Department of Dermatology, Roger Williams Medical Center, Providence, RI 02908, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Human Pathology
Verified
Journal Article
Closed access
Marshall E. KadinMarshall E. Kadin
Marshall E. Kadin
JMJohn Morgan
John Morgan
HXHaiying Xu
Haiying Xu
AEAlan L. Epstein
Alan L. Epstein
DSDavid Sieber
David Sieber
RMRoberto N. Miranda
Roberto N. Miranda

1 November 1995 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
GZGretchen M Zirbel
Gretchen M Zirbel
SGStephen E Gellis
Stephen E Gellis
Marshall E. KadinMarshall E. Kadin
Marshall E. Kadin
NENancy B Esterly
Nancy B Esterly

21 December 2020 in Cancers
Verified
Journal Article
Open access
PDF file
ADAnand Deva
Anand Deva
Suzanne TurnerSuzanne Turner
Suzanne Turner
Marshall E. KadinMarshall E. Kadin
Marshall E. Kadin
MMMark R. Magnusson
Mark R. Magnusson
H. Miles PrinceH. Miles Prince
H. Miles Prince
WAWilliam P. Adams
William P. Adams
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a CD30-positive, anaplastic lymphoma kinase-negative T-cell lymphoma. Where implant history is known, all confirmed cases to date have occurred in patients with exposure to textured implants. There is a spectrum of disease presentation, with the most common occurring as a seroma with an indolent course. A less common presentation occurs as locally advanced or, rarely, as metastatic disease. Here we review the immunological characteristics of BIA-ALCL and potential triggers leading to its development. BIA-ALCL occurs in an inflammatory microenvironment with significant lymphocyte and plasma cell infiltration and a prominent Th1/Th17 phenotype in advanced disease. Genetic lesions affecting the JAK/STAT signaling pathway are commonly present. Proposed triggers for the development of malignancy include mechanical friction, silicone implant shell particulates, silicone leachables, and bacteria. Of these, the bacterial hypothesis has received significant attention, supported by a plausible biologic model. In this model, bacteria form an adherent biofilm in the favorable environment of the textured implant surface, producing a bacterial load that elicits a chronic inflammatory response. Bacterial antigens, primarily of Gram-negative origin, may trigger innate immunity and induce T-cell proliferation with subsequent malignant transformation in genetically susceptible individuals. Although much remains to be elucidated regarding the multifactorial origins of BIA-ALCL, future research should focus on prevention and treatment strategies, recognizing susceptible populations, and whether decreasing the risk of BIA-ALCL is possible.

10 February 2017 in OncoImmunology
Verified
Journal Article
Open access
PMPilvi Maliniemi
Pilvi Maliniemi
Kirsi LaukkanenKirsi Laukkanen
Kirsi Laukkanen
LVLiisa Väkevä
Liisa Väkevä
Katja DettmerKatja Dettmer
Katja Dettmer
TLTuomas Lipsanen
Tuomas Lipsanen
ARAnnamari Ranki
Annamari Ranki
Indoleamine 2,3-deoxygenase 1 (IDO1) induces immune tolerance in the tumor microenvironment (TME) and is recognized as a potential therapeutic target. We studied the expression of both IDO1 and the related tryptophan 2,3-dioxygenase (TDO) in several different subtypes of cutaneous T-cell lymphoma (CTCL), and evaluated the kynurenine (KYN) pathway in the local TME and in patient sera. Specimens from the total of 90 CTCL patients, including mycosis fungoides (MF, n = 37), lymphomatoid papulosis (LyP, n = 36), primary cutaneous anaplastic large cell lymphoma (pcALCL, n = 4), subcutaneous panniculitis-like T-cell lymphoma (SPTCL n = 13), and 10 patients with inflammatory lichen ruber planus (LRP), were analyzed by immunohistochemistry (IHC), immunofluorescence (IF), quantitative PCR, and/or liquid chromatography–tandem mass spectrometry (LC–MS/MS). Three CTCL cell lines also were studied. Expression of both IDO1 and TDO was upregulated in CTCL. In MF specimens and in the MF cell line MyLa2000, IDO1 expression exceeded that of TDO, whereas the opposite was true for LyP, ALCL, and corresponding Mac1/2A cell lines. The spectrum of IDO1-expressing cell types differed among CTCL subtypes and was reflected in the clinical behavior. In MF, SPTCL, and LyP, IDO1 was expressed by malignant cells and by CD33+ myeloid-derived suppressor cells, whereas in SPTCL CD163+ tumor-associated macrophages also expressed IDO1. Significantly elevated serum KYN/Trp ratios were found in patients with advanced stages of MF. Epacadostat, an IDO1 inhibitor, induced a clear decrease in KYN concentration in cell culture. These results show the importance of IDO1/TDO-induced immunosuppression in CTCL and emphasize its role as a new therapeutic target.

11 April 2017 in Aesthetic Surgery Journal
Verified
Journal Article
Open access
PDF file
Marshall E. KadinMarshall E. Kadin
Marshall E. Kadin
JMJohn Morgan
John Morgan
HXHaiying Xu
Haiying Xu
CGCaroline A Glicksman
Caroline A Glicksman
The development and progression of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) remains inadequately understood. There are now more than 200 women worldwide who have been diagnosed with BIA-ALCL.1 The single most common presentation of BIA-ALCL is an accumulation of fluid (periprosthetic fluid/late seroma) occurring on average 9 to 10 years following implantation.1 The association of anaplastic lymphoma kinase (ALK)-negative ALCL arising within this fluid and the surrounding capsule has led to the description of a distinct malignancy. BIA-ALCL is CD30+, ALK-, and usually CD4+. Clonal T-cell receptor gene rearrangements have been detected in clinical specimens and cell lines derived from BIA-ALCL.1,2 High expression of JUNB (a transcription factor for which there is no known abbreviation), suppressor of cytokine signaling 3, and special AT-rich sequencing-binding protein-1 have been reported as potential biomarkers of malignant cells in BIA-ALCL, similar to cutaneous ALCL.3 In addition, recent studies have revealed a linear relationship between the number of bacteria/biofilm on the implant surface and the amount of T lymphocytic infiltrate on textured implants associated with BIA-ALCL.4

31 January 2019 in Aesthetic Surgery Journal
Verified
Journal Article
Closed access
PDF file
Marshall E. KadinMarshall E. Kadin
Marshall E. Kadin
Cytokines, their receptors, and downstream signaling partners, especially JAK1/2 and STAT3, are key biomarkers in lymphoproliferative disorders including systemic anaplastic large cell lymphoma (ALCL). Here we review their role in breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Early results suggest that, in addition to CD30, IL-9, IL-10, and IL-13 can distinguish malignant from benign seromas. IL-6 is increased in both benign and malignant seromas. IFNγ may identify a subset of BIA-ALCL with a different clinical course. Immunohistochemical detection of nuclear transcription factors—which regulate cytokine signaling—and phosphorylated janus kinases/signal transducers and activators of transcription can inform the identification and malignant potential of CD30+ cells. The innate immune response is the first line of defense against microbes suspected to initiate BIA-ALCL. Innate lymphoid cells are grouped according to the cytokines they produce and could potentially be identified as precursors to BIA-ALCL. Cytokines modulate the tumor microenvironment and hence the pathology of BIA-ALCL such as the influx of eosinophils and capsular fibrosis mediated by IL-13. The plasticity of T cells and innate immune cells theoretically can enable therapeutic manipulations toward a less aggressive phenotype. Cytokine receptors targeted in clinical trials of inflammatory and autoimmune disorders could afford opportunities for immunotherapy of BIA-ALCL.